Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Source: 
Seeking Alpha
snippet: 

Mirati Therapeutics (NASDAQ:MRTX) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncology Virtual Congress.